MXPA06000973A - Soluciones de dialisis con niveles reducidos de productos de degradacion de glucosa. - Google Patents
Soluciones de dialisis con niveles reducidos de productos de degradacion de glucosa.Info
- Publication number
- MXPA06000973A MXPA06000973A MXPA06000973A MXPA06000973A MXPA06000973A MX PA06000973 A MXPA06000973 A MX PA06000973A MX PA06000973 A MXPA06000973 A MX PA06000973A MX PA06000973 A MXPA06000973 A MX PA06000973A MX PA06000973 A MXPA06000973 A MX PA06000973A
- Authority
- MX
- Mexico
- Prior art keywords
- concentrate
- dialysis solution
- acidic
- solution
- dextrose
- Prior art date
Links
- 239000000385 dialysis solution Substances 0.000 title claims abstract description 123
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 102
- 239000008103 glucose Substances 0.000 title claims abstract description 24
- 239000007857 degradation product Substances 0.000 title claims abstract description 22
- 239000012141 concentrate Substances 0.000 claims abstract description 113
- 239000008121 dextrose Substances 0.000 claims abstract description 74
- 238000000502 dialysis Methods 0.000 claims abstract description 62
- 239000000243 solution Substances 0.000 claims abstract description 40
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims abstract description 25
- 239000003929 acidic solution Substances 0.000 claims abstract description 24
- 238000002156 mixing Methods 0.000 claims abstract description 19
- 238000001802 infusion Methods 0.000 claims abstract description 9
- 239000000872 buffer Substances 0.000 claims abstract description 7
- 229960001031 glucose Drugs 0.000 claims description 75
- 230000002378 acidificating effect Effects 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 35
- 229940001447 lactate Drugs 0.000 claims description 24
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 11
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 9
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 9
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 9
- 229960005069 calcium Drugs 0.000 claims description 9
- 239000011575 calcium Substances 0.000 claims description 9
- 229910052791 calcium Inorganic materials 0.000 claims description 9
- 239000001110 calcium chloride Substances 0.000 claims description 9
- 229960002713 calcium chloride Drugs 0.000 claims description 9
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 9
- 229960002337 magnesium chloride Drugs 0.000 claims description 9
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 9
- AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 claims description 8
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 7
- 239000011259 mixed solution Substances 0.000 claims description 7
- -1 3-deoxyglucasone Chemical compound 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 239000007853 buffer solution Substances 0.000 claims description 4
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 claims description 4
- 229940052299 calcium chloride dihydrate Drugs 0.000 claims description 4
- 229940015043 glyoxal Drugs 0.000 claims description 4
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims description 3
- NOEGNKMFWQHSLB-UHFFFAOYSA-N 5-hydroxymethylfurfural Chemical compound OCC1=CC=C(C=O)O1 NOEGNKMFWQHSLB-UHFFFAOYSA-N 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- RJGBSYZFOCAGQY-UHFFFAOYSA-N hydroxymethylfurfural Natural products COC1=CC=C(C=O)O1 RJGBSYZFOCAGQY-UHFFFAOYSA-N 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 claims description 3
- 229940091250 magnesium supplement Drugs 0.000 claims description 3
- 239000001540 sodium lactate Substances 0.000 claims description 3
- 229940005581 sodium lactate Drugs 0.000 claims description 3
- 235000011088 sodium lactate Nutrition 0.000 claims description 3
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 claims description 2
- 229940083542 sodium Drugs 0.000 claims description 2
- 239000002253 acid Substances 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 238000001631 haemodialysis Methods 0.000 description 12
- 230000000322 hemodialysis Effects 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 239000002699 waste material Substances 0.000 description 11
- 230000008901 benefit Effects 0.000 description 10
- 210000004379 membrane Anatomy 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 239000003053 toxin Substances 0.000 description 9
- 231100000765 toxin Toxicity 0.000 description 9
- 108700012359 toxins Proteins 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 210000003200 peritoneal cavity Anatomy 0.000 description 8
- 230000001954 sterilising effect Effects 0.000 description 8
- 238000004659 sterilization and disinfection Methods 0.000 description 7
- 238000011049 filling Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 208000001647 Renal Insufficiency Diseases 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000002615 hemofiltration Methods 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 201000006370 kidney failure Diseases 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 239000000470 constituent Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000003002 pH adjusting agent Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000000429 assembly Methods 0.000 description 2
- 230000000712 assembly Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000011340 continuous therapy Methods 0.000 description 2
- 238000011975 continuous veno-venous hemodiafiltration Methods 0.000 description 2
- 238000011974 continuous veno-venous hemodialysis Methods 0.000 description 2
- 238000011973 continuous veno-venous hemofiltration Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000002357 osmotic agent Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 206010034674 peritonitis Diseases 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- FHGHVYTXALBXFP-KZYINIMZSA-N (2S,3R,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O FHGHVYTXALBXFP-KZYINIMZSA-N 0.000 description 1
- ZGCHLOWZNKRZSN-NTSWFWBYSA-N 3-deoxyglucosone Chemical compound OC[C@@H](O)[C@@H](O)CC(=O)C=O ZGCHLOWZNKRZSN-NTSWFWBYSA-N 0.000 description 1
- UHPMJDGOAZMIID-UHFFFAOYSA-N 3-deoxyglucosone Natural products OCC1OC(O)C(=O)CC1O UHPMJDGOAZMIID-UHFFFAOYSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000006701 autoxidation reaction Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000476 body water Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 238000012959 renal replacement therapy Methods 0.000 description 1
- 210000005227 renal system Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- NGSFWBMYFKHRBD-DKWTVANSSA-M sodium;(2s)-2-hydroxypropanoate Chemical compound [Na+].C[C@H](O)C([O-])=O NGSFWBMYFKHRBD-DKWTVANSSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
- A61J1/2093—Containers having several compartments for products to be mixed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1654—Dialysates therefor
- A61M1/1656—Apparatus for preparing dialysates
- A61M1/1668—Details of containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
- A61M1/287—Dialysates therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/10—Bag-type containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
- A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
- A61J1/202—Separating means
- A61J1/2024—Separating means having peelable seals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
- A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
- A61J1/202—Separating means
- A61J1/2027—Separating means having frangible parts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- External Artificial Organs (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/628,065 US7053059B2 (en) | 2003-07-25 | 2003-07-25 | Dialysis solutions with reduced levels of glucose degradation products |
| PCT/US2004/022895 WO2005011631A1 (en) | 2003-07-25 | 2004-07-15 | Dialysis solutions with reduced levels of glucose degradation products |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA06000973A true MXPA06000973A (es) | 2006-04-27 |
Family
ID=34080723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA06000973A MXPA06000973A (es) | 2003-07-25 | 2004-07-15 | Soluciones de dialisis con niveles reducidos de productos de degradacion de glucosa. |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US7053059B2 (https=) |
| EP (1) | EP1648410A1 (https=) |
| JP (1) | JP2007500126A (https=) |
| MX (1) | MXPA06000973A (https=) |
| WO (1) | WO2005011631A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10155082B2 (en) | 2002-04-10 | 2018-12-18 | Baxter International Inc. | Enhanced signal detection for access disconnection systems |
| US7052480B2 (en) | 2002-04-10 | 2006-05-30 | Baxter International Inc. | Access disconnection systems and methods |
| US7022098B2 (en) | 2002-04-10 | 2006-04-04 | Baxter International Inc. | Access disconnection systems and methods |
| US20040254513A1 (en) * | 2002-04-10 | 2004-12-16 | Sherwin Shang | Conductive polymer materials and applications thereof including monitoring and providing effective therapy |
| US20070293441A1 (en) * | 2003-09-22 | 2007-12-20 | Baxter International Inc. | High-pressure sterilization to terminally sterilize pharmaceutical preparations and medical products |
| US20050276868A1 (en) * | 2004-06-10 | 2005-12-15 | Bart Degreve | Bicarbonate-based peritoneal dialysis solutions |
| US7384558B2 (en) * | 2004-07-26 | 2008-06-10 | Baxter International Inc. | Compositions capable of inhibiting reactive oxygen and carbonyl species |
| US7935070B2 (en) | 2005-01-28 | 2011-05-03 | Fresenius Medical Care North America | Systems and methods for dextrose containing peritoneal dialysis (PD) solutions with neutral pH and reduced glucose degradation product |
| WO2006115067A1 (ja) * | 2005-04-20 | 2006-11-02 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | 腹膜透析液 |
| US8133194B2 (en) * | 2006-02-22 | 2012-03-13 | Henry Ford Health System | System and method for delivery of regional citrate anticoagulation to extracorporeal blood circuits |
| US8211048B2 (en) * | 2006-02-22 | 2012-07-03 | Henry Ford Health System | System and method for delivery of regional citrate anticoagulation to extracorporeal blood circuits |
| JP4004523B1 (ja) * | 2006-04-21 | 2007-11-07 | 株式会社日本トリム | 透析液調製用水およびそれを用いた透析液、透析液の製造方法ならびに透析装置 |
| FR2925341A1 (fr) * | 2007-12-20 | 2009-06-26 | Gambro Lundia Ab | Appareil pour le traitement extracorporel de sang ou plasma recevant plusieurs articles a usage unique |
| US20090214807A1 (en) | 2008-02-27 | 2009-08-27 | Shawn Davis | Peelable seals including porous inserts |
| US8114043B2 (en) | 2008-07-25 | 2012-02-14 | Baxter International Inc. | Electromagnetic induction access disconnect sensor |
| US9585810B2 (en) | 2010-10-14 | 2017-03-07 | Fresenius Medical Care Holdings, Inc. | Systems and methods for delivery of peritoneal dialysis (PD) solutions with integrated inter-chamber diffuser |
| US9861733B2 (en) | 2012-03-23 | 2018-01-09 | Nxstage Medical Inc. | Peritoneal dialysis systems, devices, and methods |
| EP2688602B1 (en) | 2011-03-23 | 2019-11-06 | NxStage Medical, Inc. | Peritoneal dialysis systems, devices, and methods |
| AU2012272483B2 (en) | 2011-06-24 | 2016-06-16 | Lo, Richard W. C. | Multi-container systems and uses thereof |
| EP3482786B1 (en) * | 2012-03-23 | 2023-12-13 | NxStage Medical, Inc. | Peritoneal dialysis systems and devices |
| CN103006555B (zh) * | 2013-01-05 | 2014-08-06 | 四川美大康佳乐药业有限公司 | 一种羟乙基淀粉注射液及其制备方法 |
| US10518014B2 (en) * | 2015-10-30 | 2019-12-31 | Nxstage Medical, Inc. | Treatment fluid devices methods and systems |
| JP7032321B2 (ja) | 2016-05-06 | 2022-03-08 | ガンブロ・ルンディア・エービー | 配分液体用システム |
| WO2017191302A1 (en) | 2016-05-06 | 2017-11-09 | Gambro Lundia Ab | Dialysis concentrate |
| SG11201910175RA (en) * | 2017-05-05 | 2019-11-28 | Fresenius Medical Care Deutschland Gmbh | Peritoneal dialysis concentrate, peritoneal dialysis bag and set for continuous ambulatory peritoneal dialysis or automated peritoneal dialysis |
| WO2018237375A1 (en) | 2017-06-24 | 2018-12-27 | Nxstage Medical, Inc. | Peritoneal dialysis fluid preparation and/or treatment devices methods and systems |
| US20190262526A1 (en) | 2018-02-28 | 2019-08-29 | Nxstage Medical, Inc. | Fluid Preparation and Treatment Devices Methods and Systems |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4879280A (en) | 1981-09-24 | 1989-11-07 | Fresenius Ag | Dialysis solution for use in intraperitoneal dialysis |
| EP0076355A3 (en) | 1981-10-01 | 1983-05-25 | Abbott Laboratories | Improved peritoneal dialysis solution |
| GB8404299D0 (en) | 1984-02-18 | 1984-03-21 | Milner Research Ireland Ltd | Peritoneal dialysis |
| GB8300718D0 (en) | 1983-01-12 | 1983-02-16 | Milner Research Ireland Ltd | Glucose polymer solutions |
| US4886789A (en) | 1983-01-12 | 1989-12-12 | M. L. Laboratories Plc | Peritoneal dialysis and compositions for use therein |
| US6077836A (en) | 1983-01-12 | 2000-06-20 | Ml Laboratotries, Plc | Peritoneal dialysis and compositions for use therein |
| US4604379A (en) | 1984-06-18 | 1986-08-05 | Curators Of The University Of Missouri | Dialysis solutions containing cross-linked gelatin |
| JPS61502943A (ja) | 1984-06-22 | 1986-12-18 | ビ−チ、リチャ−ド・エル | 電解質溶液およびその生体内における使用 |
| DE3428201A1 (de) | 1984-07-31 | 1986-02-06 | Laevosan-Gesellschaft mbH & Co. KG, Linz | Loesungen fuer die peritonealdialyse |
| JPS61247466A (ja) | 1985-04-25 | 1986-11-04 | テルモ株式会社 | 腹膜透析用透析液 |
| DE3689863T2 (de) | 1985-06-22 | 1995-01-05 | Ml Lab Plc | In kontinuierlicher Peritonealdialyse verwendete Polymere. |
| GB8521712D0 (en) | 1985-08-31 | 1985-10-02 | Giltech Ltd | Solution for peritoneal dialysis |
| DE3683583D1 (de) | 1985-09-10 | 1992-03-05 | Res Corp Technologies Inc | Osmotische mittel fuer peritonealdialyse. |
| US4976683A (en) | 1986-06-20 | 1990-12-11 | Abbott Laboratories | Peritoneal dialysis method |
| GR870129B (en) | 1987-01-27 | 1987-02-04 | Giatzidis Ippokratis | Stable bicarbonate - glycylglycine dialysate for hemodialysis and peritoneal dialysis |
| DE3812525C1 (https=) | 1988-04-15 | 1989-06-22 | Fresenius Ag, 6380 Bad Homburg, De | |
| DE3821043A1 (de) | 1988-06-22 | 1989-12-28 | Fresenius Ag | Dialysier- und spuel-loesung zur intraperitonealen verabreichung |
| DE4123001A1 (de) | 1991-07-11 | 1993-01-14 | Laevosan Gmbh & Co Kg | Pharmazeutische zusammensetzung fuer die peritonealdialyse |
| SE9103395D0 (sv) | 1991-11-18 | 1991-11-18 | Gambro Ab | System med anvaendning av ensteril medicinsk loesning innehaallande glukos eller glukosliknande aemnen samt en loesning avsedd foer detta system |
| DE4242926C2 (de) | 1992-12-18 | 1994-12-15 | Fresenius Ag | Dialyselösung für die Peritonealdialyse |
| SG48090A1 (en) | 1993-01-19 | 1998-04-17 | Baxter Int | Multiple chamber container |
| US5436232A (en) | 1994-01-07 | 1995-07-25 | Laevosan-Gesellschaft Mbh | Pharmaceutical composition for peritoneal dialysis |
| JPH07252137A (ja) | 1994-02-21 | 1995-10-03 | Terumo Corp | 糖類含有電解質溶液 |
| GB9411009D0 (en) | 1994-06-02 | 1994-07-20 | Giltech Ltd | Dialysis fluid |
| SE510030C2 (sv) | 1995-08-08 | 1999-04-12 | Gambro Ab | Förfarande för blandning av steril medicinsk lösning samt behållare för utförande av förfarandet |
| CA2155910C (en) | 1995-08-11 | 1999-12-14 | George Wu | Biocompatible aqueous solution for use in continuous ambulatory peritoneal dialysis |
| SE9600631D0 (sv) | 1996-02-20 | 1996-02-20 | Gambro Ab | Use of a solution comprising glucose for peritonial dialysis having reduced formation of AGE products |
| GB9714218D0 (en) | 1997-07-04 | 1997-09-10 | Allied Therapeutics Ltd | Peritoneal dialysis fluid |
| WO1999009953A1 (fr) | 1997-08-22 | 1999-03-04 | Shimizu Pharmaceutical Co., Ltd. | Preparation contenant du glucose |
| DE19748290B8 (de) | 1997-10-31 | 2009-09-03 | Fresenius Medical Care Deutschland Gmbh | Lösung für die Peritonealdialyse |
| DE69929550T8 (de) | 1998-05-21 | 2006-12-28 | Nipro Corp. | Albumin enthaltende Lösung für die Peritonealdialyse |
| DE69929555T8 (de) | 1998-06-17 | 2007-05-31 | Nipro Corp. | Verwendung einer Flüssigkeit zur Herstellung einer Dialyselösung für die kontinuierliche rezirkulierende Peritonealdialyse |
| SG72966A1 (en) * | 1998-07-08 | 2000-05-23 | Sumitomo Chemical Co | Transition metal compound olefin polymerization catalyst component olefin polymerization catalyst and process for producing olefin polymer |
| JP2000037452A (ja) | 1998-07-21 | 2000-02-08 | Terumo Corp | 腹膜透析液 |
| EG24303A (en) | 1998-10-20 | 2009-01-12 | Advanced Renal Technologies | Buffered compositions for dialysis |
| JP4284737B2 (ja) | 1999-02-26 | 2009-06-24 | 株式会社ジェイ・エム・エス | 中性腹膜透析液 |
| US6309673B1 (en) | 1999-09-10 | 2001-10-30 | Baxter International Inc. | Bicarbonate-based solution in two parts for peritoneal dialysis or substitution in continuous renal replacement therapy |
| JP4638106B2 (ja) | 1999-10-11 | 2011-02-23 | シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ | 医薬的使用のための溶液中における浸透圧剤としての、ｌ−カルニチンおよびそのアルカノイル誘導体の使用 |
| ATE311203T1 (de) | 1999-10-15 | 2005-12-15 | Dow Global Technologies Inc | Dialyselösung die polyglycol als osmotischen mittels enthält |
| US6787039B2 (en) | 2001-01-26 | 2004-09-07 | Degussa Ag | Amino acid composition for hemodialysis |
| JP2002282354A (ja) | 2001-03-27 | 2002-10-02 | Jms Co Ltd | 腹膜透析液 |
| GB0108359D0 (en) | 2001-04-03 | 2001-05-23 | Allied Therapeutics Ltd | Peritoneal dialysis fluid |
| EP1377594A4 (en) | 2001-04-10 | 2004-06-30 | Danisco Usa Inc | POLYMERIZATION OF MONO- AND DISACCHARIDES WITH MONOCARBOXYLIC ACIDS AND LACTONES |
| WO2003013553A1 (es) | 2001-08-10 | 2003-02-20 | Van Dyck Diaz Rodolfo Candelar | Fórmula de solución dialítica y procedimiento de diálisis gastrointestinal |
| DE10217356B4 (de) | 2002-04-18 | 2012-03-29 | Fresenius Medical Care Deutschland Gmbh | Lösung für die Peritonealdialyse |
-
2003
- 2003-07-25 US US10/628,065 patent/US7053059B2/en not_active Expired - Fee Related
-
2004
- 2004-07-15 EP EP04778412A patent/EP1648410A1/en not_active Ceased
- 2004-07-15 WO PCT/US2004/022895 patent/WO2005011631A1/en not_active Ceased
- 2004-07-15 JP JP2006521141A patent/JP2007500126A/ja active Pending
- 2004-07-15 MX MXPA06000973A patent/MXPA06000973A/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007500126A (ja) | 2007-01-11 |
| WO2005011631A1 (en) | 2005-02-10 |
| US7053059B2 (en) | 2006-05-30 |
| US20050020507A1 (en) | 2005-01-27 |
| EP1648410A1 (en) | 2006-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7053059B2 (en) | Dialysis solutions with reduced levels of glucose degradation products | |
| EP1465688B9 (en) | Bicarbonate-based solutions for dialysis therapies | |
| AU2003299683B2 (en) | Biocompatible dialysis fluids containing icodextrins | |
| JP5690040B2 (ja) | 重炭酸塩ベースの腹膜透析溶液 | |
| US20250032435A1 (en) | Dialysis concentrate | |
| JPH02196724A (ja) | 腹膜透析液 | |
| HK1088535B (en) | Biocompatible dialysis fluids containing icodextrins | |
| HK1144548B (en) | Sterilised dialysis solutions containing pyrophosphates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |